Feature | December 09, 2014

Near-Infrared Spectroscopy May Predict Risk of Future Heart Attack and Stroke

Study using Infraredx's TVC Imaging System to identify lipid-core plaque that can lead to major adverse cardiac and cerebrovascular events

near-infrared spectroscopy, NIRS, heart attack, stroke, Infraredx, TVC

Image courtesy of Infraredx

December 9, 2014 — A study published in the Journal of the American College of Cardiology (JACC) shows intravascular near-infrared spectroscopy (NIRS) can identify lipid core-containing plaques, implicated in most heart attacks. The study shows the technology might be used as a means to predict the risk of future major adverse cardiac and cerebrovascular events (MACCE).

In the study, patients who presented with symptoms associated with limited blood supply to the heart also underwent NIRS imaging to evaluate the Lipid Core Burden Index (LCBI) in an artery that was not directly implicated in causing their symptoms. The results, which were published online on Dec. 8 and will appear in the Dec. 16 print edition of JACC, demonstrated that patients with an LCBI ? 43 in a non-culprit artery had a fourfold risk of MACCE such as heart attack or stroke within the following year. In addition, the study concluded that non-culprit vessel LCBI reflects vascular vulnerability of the larger coronary tree.

Lipid-core plaque is a type of fatty coronary artery plaque suspected to be prone to rupture, which leads to the formation of blood clots that can cause heart attacks. Only NIRS can detect lipid-core plaque and provide a quantitative measurement in the form of an LCBI. Intravascular NIRS is commercially available through the TVC Imaging System from Infraredx Inc., a U.S. Food and Drug Administration (FDA)-cleared dual-modality imaging system capable of rapidly, specifically and reliably identifying lipid-core plaques using NIRS and providing vessel structure information using enhanced intravascular ultrasound (IVUS).

“Our findings suggest that the use of NIRS imaging to identify and quantify lipid-core plaque in the non-culprit arteries, which would otherwise remain undetected by coronary angiography, could be a viable tool to assess the vascular vulnerability of the larger coronary tree,” said Rohit M. Oemrawsingh, M.D., M.Sc, the study’s first author at the Thoraxcenter, department of cardiology, Erasmus MC, Rotterdam, the Netherlands.

The ATHEROREMO-NIRS Study, a sub-study of the European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis (ATHEROREMO), is a prospective, single-center, observational study that enrolled 203 patients referred for coronary angiography due to stable angina (chest pain) or an acute coronary syndrome (ACS), a combination of symptoms resulting from the blockage of blood supply to the heart. NIRS imaging was performed and an LCBI measurement was obtained for a pre-defined segment of a non-culprit coronary artery that was at least 40 mm in length and with < 50 percent stenosis confirmed by angiography. The primary endpoint was the incidence of MACCE, defined as all-cause mortality, non-fatal ACS, stroke and unplanned coronary revascularization during one-year follow-up.

The research team hopes that the ongoing Lipid-Rich Plaque Study and PROSPECT II/ABSORB Study will provide further validation of their results. 

For more information: www.infraredx.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init